Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Dexon Pharmaceuticals Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 distinct examiners across 2 distinct art units, creating examiner variation with some shared technical examination context. Counsel can develop consistent pharmaceutical terminology and support standards, while tailoring claim amendments to each examiner and art-unit record.
BERTOGLIO, VALARIE E is the busiest examiner, with 1 pending matter. The examiner does not hold a concentrated portion of the docket, so portfolio management should emphasize issue tracking across the separate matters. Clear linkage among claimed compounds, uses, processes, and disclosure support can help keep responses focused without assuming identical examination treatment.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.3% |
| CURRENS, GRANT CARSON | 1 | 54.9% | +60.1% |
| TAKENAKA, RISA | 1 | 26.1% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17928103 | METHOD FOR PREVENTING INFECTION OF A HEALTHY PERSON OR A HEALTHY ANIMAL WITH A VIRUS THAT USES ACE2 AS A RECEPTOR, BINDING INHIBITOR AND MEDICAL DEVICE | TAKENAKA, RISA | 15d overdue |
| 18828791 | AGENT FOR IMPROVING CANCER CACHEXIA AND METHOD FOR IMPROVING CANCER CACHEXIA | BERTOGLIO, VALARIE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17928103 | METHOD FOR PREVENTING INFECTION OF A HEALTHY PERSON OR A HEALTHY ANIMAL WITH A VIRUS THAT USES ACE2 AS A RECEPTOR, BINDING INHIBITOR AND MEDICAL DEVICE | TAKENAKA, RISA | 15d overdue |
| 18828791 | AGENT FOR IMPROVING CANCER CACHEXIA AND METHOD FOR IMPROVING CANCER CACHEXIA | BERTOGLIO, VALARIE E | — |
| 18024997 | CYTOKINE STORM SUPPRESSOR, METHOD FOR USING CYTOKINE STORM SUPPRESSOR AND SCREENING METHOD | CURRENS, GRANT CARSON | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18828791 | AGENT FOR IMPROVING CANCER CACHEXIA AND METHOD FOR IMPROVING CANCER CACHEXIA | BERTOGLIO, VALARIE E | — | §103§112 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18024997 | CYTOKINE STORM SUPPRESSOR, METHOD FOR USING CYTOKINE STORM SUPPRESSOR AND SCREENING METHOD | CURRENS, GRANT CARSON | 1651 | §103§112DP | Non-Final OA | — | Pending | Mar 07, 2023 |
| 17928103 | METHOD FOR PREVENTING INFECTION OF A HEALTHY PERSON OR A HEALTHY ANIMAL WITH A VIRUS THAT USES ACE2 AS A RECEPTOR, BINDING INHIBITOR AND MEDICAL DEVICE | TAKENAKA, RISA | 1632 | §112 | Non-Final OA | 15d overdue | Pending | Nov 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDexon Pharmaceuticals Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Valarie E Bertoglio has the most, with 1 of Dexon Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
